- Diabetes Research News
- January 19, 2018
Patents Approved for Small Molecule Therapies for Type 1 Diabetes
There are numerous approaches to managing, treating, and potentially curing type 1 diabetes (T1D). Some focus on replenishing or protecting insulin-producing beta cells, some involve the development of devices that simulate similar functions, and still, others seek to zero in on issues related to the development of T1D.
ImmunoMolecular Therapeutics recently received patents for two of its small molecule therapies that can be used in the treatment of T1D. These patents provide exclusive rights to the use of methyldopa and D-methyldopa (D-MDOPA) as part of immunotherapy treatment. According to the company, βThe lead candidate drug [D-MDOPA] is an oral small molecule that starves the autoimmune process in type 1 diabetes by blocking DQ8 on specific immune cells. Our goal is to preserve pancreatic beta cell function and maintain normal insulin production in at-risk and early-stage patients with type 1 diabetes.β By blocking DQ8, the immune system will not attack insulin-producing beta cells, therefore, preserving their function.
Immunotherapy is one option when it comes to treating T1D. The Diabetes Research Connection supports early career scientists in moving forward with novel research for a variety of methods used in the treatment and prevention of the disease. To learn more about current projects and support their advancement, visit http://diabetesresearchconnection.org.